NBY - רווח לפני ריבית, מסים ופחת novabay.com
NovaBay Pharmaceuticals generates revenue through the sale of the antimicrobial agent Avenova and related eyelid products. The company's consolidated EBITDA reflects cash flow dynamics, with the value fixed at 0.00. The business is currently focusing on organic growth via online retail while divesting non-core assets. However, pricing pressure in the over-the-counter segment and the risk of losing customer loyalty pose threats to revenue.
NovaBay Pharmaceuticals, Inc. - פילוחים אנליטיים ומדדי מפתח (NBY)
This indicator measures net cash flow from operating activities before depreciation and debt service costs, allowing investors to assess the business's fundamental ability to generate cash. An analysis of the overall EBITDA of NovaBay Pharmaceuticals (NBY) reveals the sensitivity of earnings to rising marketing expenses, which NovaBay Pharmaceuticals requires to protect its market position amid intense pressure from generic manufacturers.
